Nutra Pharma Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Nutra Pharma's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Sep 2022

Recent past performance updates

No updates

Recent updates

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Nutra Pharma has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.

Show section

Revenue & Expenses Breakdown
Beta

How Nutra Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:NPHC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 220710
30 Jun 2202220
31 Mar 2202620
31 Dec 210-1320
30 Sep 210-1720
30 Jun 210-3220
31 Mar 210-3710
31 Dec 200-110
30 Sep 200-310
30 Jun 200-410
31 Mar 200-410
31 Dec 190-710
30 Sep 190-310
30 Jun 190-420
31 Mar 190-320
31 Dec 180-420
30 Sep 180-420
30 Jun 180-410
31 Mar 180-410
31 Dec 170-410
30 Sep 170-420
30 Jun 170-420
31 Mar 170-320
31 Dec 160-320
30 Sep 160-220
30 Jun 160-560
31 Mar 160-660
31 Dec 150-560
30 Sep 150-760
30 Jun 151-330
31 Mar 151-330
31 Dec 141-330
30 Sep 140-230
30 Jun 140-530
31 Mar 140-420
31 Dec 130-420
30 Sep 130-630
30 Jun 130-430

Quality Earnings: Insufficient data to determine if NPHC has high quality earnings.

Growing Profit Margin: Insufficient data to determine if NPHC's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if NPHC's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare NPHC's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if NPHC's earnings growth over the past year exceeded the Biotechs industry average.


Return on Equity

High ROE: NPHC has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.